Table 2.
Baseline characteristics of the validation cohorts.
| ATB | Untreated LTBI | |
|---|---|---|
| Leiden (national cohort) | n = 12 | n = 20 |
| Male sex, n (%) | 9 (75%) | 11 (55%) |
| Age (years), mean ± SD | 37 ± 23 | 35 ± 11 |
| Pulmonary TB, n (%) | 10 (83%) | 0 |
| TB high burden countries*, n (%) | 5 (42%) | 7 (35%) |
| ATB | HH-LTBI | |
| Italy (international cohort) | n = 31 | n = 20 |
| Male sex, n (%) | 17 (55%) | 5 (25%) |
| Age (years), mean ± SD | 40 ± 14 | 44 ± 16 |
| Pulmonary TB, n (%) | 31 (100%) | 0 |
| TB high burden countries*, n (%) | 21 (68%) | 2 (11%) |
ATB, active tuberculosis; Untreated LTBI, latent tuberculosis infection without prophylaxis; Households, individuals diagnosed with untreated LTBI who shared their households with ATB patient before inclusion within the cohort; n, sample size; SD, standard deviation; TB, tuberculosis.
*Defined as a country of origin with a TB incidence of more than 50 cases per 100.000 citizens annually.